Table 1.
ICP8 mutant | Protein expression | Protein localization | % Complementation |
ICP8 WT | Yes | Nuclear | 100 |
Y20A–F61A–Y90A | Yes | Cytoplasmic | 0 |
C116A–R120A | Yes | Nuclear | 70 |
R262A–H266A | Yes | Nuclear | 14 |
R644A–D645A | Yes | Nuclear | 54 |
Q706A–F707A | Yes | Nuclear | 0 |
N882A–L883A | Yes | Nuclear | 14 |
D905A–Y909A | No | N/A | N/A |
Table showing the analysis of alanine substitution mutants assessed in this study. Vero cells were transiently transfected with 50 ng of mammalian expression plasmids containing ether WT or mutant versions of ICP8 and analyzed by Western blot and IF with anti-ICP8 antibody for protein expression and localization, respectively. For complementation analysis, transfected Vero cells were superinfected with HD-2 at an MOI of 3 for 24 h. Virus was harvested and titrated on the ICP8-complementing cell line (S2). Viral plaques were counted and reported as a percentage of WT ICP8. Results for Q706A and F707A mutant are in bold.